Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ann Q. Shen"'
Autor:
Ann Q. Shen, Alyssa Dalen, Laura Bankers, Shannon R. Matzinger, Colin Schwensohn, Kane Patel, Kelley B. Hise, Evelyn Pereira, Jennifer Cripe, Rachel H. Jervis
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 72:513-516
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9aa19289d1cfbfdadf02b1d4433a7fe1
https://doi.org/10.15585/mmwr.mm7219a2
https://doi.org/10.15585/mmwr.mm7219a2
Publikováno v:
Expert review of hematology. 9(5)
Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7ec0db8dc5b9bbfcacdd9101aa27d9
https://pubmed.ncbi.nlm.nih.gov/26853281
https://pubmed.ncbi.nlm.nih.gov/26853281
Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c5c7e89f13cca5a9af44dc4d58ba4e
https://europepmc.org/articles/PMC3891288/
https://europepmc.org/articles/PMC3891288/
Publikováno v:
The Oncologist. 19:e14-e14
On October 26, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval to omacetaxine mepesuccinate (Synribo; Teva Pharmaceuticals USA, Inc., North Wales, PA, http://www.tevausa.com) for the treatment of adult patients with chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e808e8c8ee3df4d910f855e0edcd18d
https://doi.org/10.1634/theoncologist.2014-0230
https://doi.org/10.1634/theoncologist.2014-0230